ASLAN Pharmaceuticals

Singapore, Singapore Founded: 2010 • Age: 16 yrs
Targeted small molecules are developed for oncology treatments.
Request Access

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals is a company based in Singapore (Singapore) founded in 2010.. ASLAN Pharmaceuticals has raised $100 million across 9 funding rounds from investors including Haitong International Securities Group, Tianda Pharmaceutical and K2 HealthVentures. ASLAN Pharmaceuticals operates in a competitive market with competitors including UNION Therapeutics, Concerto Biosciences, Biosion, Forte Biosciences and PinCell, among others.

  • Headquarter Singapore, Singapore
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Aslan Pharmaceuticals Pte Ltd
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
    $-46.34 M
    -55
    as on Dec 31, 2022
  • EBITDA
    $-45.89 M
    -57
    as on Dec 31, 2022
  • Total Equity Funding
    $100 M (USD)

    in 9 rounds

  • Latest Funding Round
    $20 M (USD), Post-IPO

    Mar 02, 2023

  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal
People of ASLAN Pharmaceuticals
Headcount 50-200
Employee Profiles 5
Board Members and Advisors 8
Employee Profiles
People
Stephen Doyle
Chief Business Officer
People
Alex Kaoukhov
Chief Medical Officer
People
Ben Goodger
General Counsel
People
Kiran Asarpota
COO

Unlock access to complete

Board Members and Advisors
people
Lawrence Eichenfield
Scientific Advisor
people
Melinda Gooderham
Scientific Advisor
people
Peter Foley
Scientific Advisor
people
Eric Simpson
Scientific Advisor

Unlock access to complete

Funding Insights of ASLAN Pharmaceuticals

ASLAN Pharmaceuticals has successfully raised a total of $100M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $20 million completed in March 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 9
  • Last Round Post-IPO — $20.0M
  • First Round
  • Investors Count 14
Date Amount Transaction Name Valuation Lead Investors Investors
Mar, 2023 Amount Post-IPO - ASLAN Pharmaceuticals Valuation

investors

Feb, 2021 Amount Post-IPO - ASLAN Pharmaceuticals Valuation

investors

Oct, 2019 Amount Debt – Conventional - ASLAN Pharmaceuticals Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in ASLAN Pharmaceuticals

ASLAN Pharmaceuticals has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Haitong International Securities Group, Tianda Pharmaceutical and K2 HealthVentures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Flexible, long-term financing solutions are provided to healthcare companies.
Founded Year Domain Location
US private equity investments are managed by BVF Partners.
Founded Year Domain Location
Venture capital investments are managed by Top Taiwan.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by ASLAN Pharmaceuticals

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - ASLAN Pharmaceuticals

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Aslan Pharmaceuticals Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of ASLAN Pharmaceuticals

ASLAN Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as UNION Therapeutics, Concerto Biosciences, Biosion, Forte Biosciences and PinCell, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Small molecule antibiotics are developed for bacterial infections.
domain founded_year HQ Location
Microbe-based products are developed for agriculture and human health.
domain founded_year HQ Location
Antibody-based therapeutics are developed for treating various diseases.
domain founded_year HQ Location
Therapeutic solutions for inflammatory skin diseases are developed.
domain founded_year HQ Location
Developer of anti-inflammatory therapy for the treatment skin diseases
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Aslan Pharmaceuticals

Frequently Asked Questions about ASLAN Pharmaceuticals

When was ASLAN Pharmaceuticals founded?

ASLAN Pharmaceuticals was founded in 2010.

Where is ASLAN Pharmaceuticals located?

ASLAN Pharmaceuticals is headquartered in Singapore, Singapore.

Is ASLAN Pharmaceuticals a funded company?

ASLAN Pharmaceuticals is a funded company, having raised a total of $100M across 9 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $3M, raised on Jul 27, 2010.

What does ASLAN Pharmaceuticals do?

ASLAN Pharmaceuticals was founded in 2010 in Singapore as an oncology-focused entity. Targeted drugs are developed for gastric, bile duct, and breast cancers through a proprietary pipeline of four candidates. These address indications including gastric and breast cancers plus inflammatory diseases. ASLAN001, a pan-HER inhibitor, advances in phase 2 for gastric cancer and extends to cholangiocarcinoma and breast cancer. ASLAN002 targets RON and cMET receptors for gastric and breast applications.

Who are the top competitors of ASLAN Pharmaceuticals?

ASLAN Pharmaceuticals's top competitors include Concerto Biosciences, UNION Therapeutics and Biosion.

Who are ASLAN Pharmaceuticals's investors?

ASLAN Pharmaceuticals has 14 investors. Key investors include Haitong International Securities Group, Tianda Pharmaceutical, K2 HealthVentures, BVF Partners, and Top Taiwan.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available